Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of GN-037 Cream for Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Healthy Volunteers~1. Male and female healthy volunteers aged 18-65 years\*~2. Volunteers who were informed about participation in the study and agreed to give their written informed consent.~3. Volunteers with negative qPCR SARS-CoV-2 result in nasopharyngeal or sputum samples~4. Volunteers in good general health (without any known disease in the history and physical examination in the 14 days before participating in the study)~5. Volunteers with negative HIV, Hepatitis B and C tests~6. Volunteers with negative alcohol breath test~7. Volunteers with negative urine addictive drug screening test (amphetamine, barbiturate, benzodiazepine, cannabinoid, cocaine, opiate)~8. Volunteers who agreed not to be exposed to the direct sun light during the study~9. Female volunteers of childbearing potential must have a negative pregnancy test at the screening visit and must agree to use an effective method of contraception throughout the study~10. Volunteers who can comply with all scheduled visits, laboratory tests and other study procedures \* The principal investigator will take the necessary measures to ensure that the representation~Exclusion Criteria Healthy Volunteers~1. Subjects with known hypersensitivity to any component of the study drug~2. Female volunteers who are pregnant or breastfeeding or have a positive pregnancy test~3. Volunteers with a history of chronic or acute infections requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to the screening visit~4. Patients with skin atrophy, pigmentation or extensive scarring that would preclude study evaluation at targeted treatment sites~5. Patients with other inflammatory skin disease (eg, atopic dermatitis, contact dermatitis, eczema, tinea corporis) that, in the investigator's opinion, may affect study evaluations at targeted treatment sites~6. Volunteers using moisturizing or skin softening ointment/lotion/cream on their intended treatment site within 3 days prior to enrollment in the study.~7. Volunteers who cannot come to the study center for follow-up visits~8. Volunteers taking part in another clinical study concurrently~9. Volunteers with positive urine addictive drug screening test and/or alcohol test~Inclusion Criteria For psoriatic patients~1. Male and female patients aged 18-65 years\*~2. Patients who were informed about participation in the study and agreed to give their written informed consent.~3. Patients with negative qPCR SARS-CoV-2 result in nasopharynx or sputum samples~4. Patients diagnosed with plaque psoriasis by a dermatologist at least 6 months before inclusion in the study~5. Patients whose lesions are less than 5% of the body surface area (BSA)~6. Patients who did not receive local or systemic treatment for plaque psoriasis, or who received the last psoriasis treatment 28 days or more before~7. Patients who are confirmed to be healthy by medical history and physical examination and who do not have any clinically significant disease/condition other than plaque psoriasis that could affect the study evaluation.~8. Patients with disease severity with Physician's Global Assessment (IGA) score ≥3 (moderate) as an overall assessment of all lesions to be treated~9. Patients with negative HIV, Hepatitis B and C tests~10. Patients with negative alcohol breath test~11. Patients with negative urine addictive drug screening test (amphetamine, barbiturate, benzodiazepine, cannabinoid, cocaine, opiate)~12. Patients who agreed not to be exposed to the sun during the study~13. Female patients of childbearing potential must have a negative pregnancy test at the screening visit and must agree to use an effective method of contraception throughout the study~14. Patients who can comply with all scheduled visits, laboratory tests, and other study procedures \* The principal investigator will take the necessary measures to ensure that the representation of females and males is equal.~Exclusion criteria For psoriatic patients~1. Patients with known hypersensitivity to any component of the study drug~2. Pregnant or lactating or female patients with a positive pregnancy test~3. Patients who require any other medication (topical or systemic) that may affect the course of the disease during the study period (eg antibiotics, antihistamines)~4. Patients with a history of chronic or acute infections requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to the screening visit~5. Patients with skin atrophy, pigmentation, or extensive scarring that would preclude evaluation of study drug efficacy at targeted treatment sites~6. Patients with other inflammatory skin disease (eg, atopic dermatitis, contact dermatitis, eczema, tinea corporis) that, in the investigator's opinion, may affect study evaluations at targeted treatment sites~7. Patients diagnosed with pustular, guttate, inverse, exfoliative or erythrodermic psoriasis at targeted treatment sites~8. Patients with a history of psoriasis unresponsive to topical treatments~9. Patients who used moisturizer or skin softening ointment/lotion/cream to the intended treatment areas within 3 days prior to enrolling in the study.~10. Patients who cannot come to the study center for follow-up visits~11. Patients taking part in another clinical study concurrently~12. Patients with positive urine addictive drug screening test and/or alcohol test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- GN 037 cream (Type: EXPERIMENTAL): Healthy volunteers will receive GN037 cream in 2 to 1 ration~Application will be done twice daily, to selected area of body on the fore arm:~Increasing dosages of dosages: Low dose to a 5 cm2 skin area, Medium dose to15 cm2 skin area, High dose to 30 cm2 skin area~Psoriatic patients will receive GN037 cream Aplication twice daily, to a selected body target lesion High dose 30 cm2
- Placebo Cream (Type: PLACEBO_COMPARATOR): Placebo cream will be applied in 2 to 1 ratio twice daily, to selected area of fore arm.~Low dose to 5 cm2 skin area, Medium dose 15 cm2 skin area, High dose 30 cm2 skin area

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete